An observational study in Analytical Reproducibility of a Medical Device, sponsored by Spartan Bioscience Inc.. Completed at 3 sites in Canada. Open to participants aged 16 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-01-07.
Sponsored by Spartan Bioscience Inc. · Observational
The Spartan FRX CYP2C19 Test System (hereafter referred to as the 'FRX System') is a qualitative in vitro diagnostic test for the identification of a patient's CYP2C19 *2, *3 and *17 genotypes from genomic DNA obtained from buccal swab samples. The objective of the study is to evaluate the performance of the FRX System under multivariate conditions including different days, sites, operators and systems.
The FRX system is comprised of hardware and consumable components. The hardware components of the system include an Analyzer (thermal cycler with fluorescence detection capability), a notebook computer and a printer. The consumable component of the FRX system is a sample collection kit. Each kit contains a buccal swab (used to collect the patient sample) and a tube containing the reagents required for genomic DNA extraction and PCR (polymerase chain reaction) amplification stages of the test.
The Spartan FRX System is capable of detecting three CYP2C19 SNPs(single nucleotide polymorphism) (*2, *3, *17) in each test performed. An individual sample collection kit is required for each SNP tested; therefore three sample collection kits are required for each test performed on the system.
To perform a test, the user collects three buccal samples from the patient and then inserts a sample into each of the three reagent tubes (one for each of the CYP2C19 loci *2, *3 and *17). The reagent tubes are placed into the Analyzer and the FRX system automates the processes of DNA extraction, PCR amplification, fluorescent signal detection and data analysis. The system provides the user with a printed result listing the patient genotypes at the *2, *3 and *17 loci.
The objective of the study is to evaluate the performance of the FRX System under multivariate conditions. Specifically, the following variables will be included in the study:
Test performance is defined as the number of correct genotype calls, expressed as a percentage of the total number of tests performed on the system.
For both the first-pass and second-pass results, 1-sided 95% confidence lower limits will be calculated using the score method for the % correct calls (i.e. % agreement).
Genotype results from the FRX system will be compared with results of DNA sequencing. The result of the FRX System test will be determined to be correct if the genotype calls for all three SNPs are identical to the genotypes determined by DNA sequencing for that sample/individual.
Results of the Reproducibility Study will be acceptable if the lower bound of a 1-sided 95% confidence limit of the total correct call rate per genotype is greater than or equal to 95%, based on second-pass results.
Spartan Bioscience Inc. is the lead sponsor of 7 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
8 Individuals with predetermined CYP2C19 *2,*3 and *17 genotypes
Exclusion Criteria:
Percentage of Correct Calls to Assess Reproducibility of the Spartan FRX CYP2C19 System.
Reproducibility was calculated as a percentage of the correct calls over the total calls made for each genotype group. All calls were made using the Spartan FRX CYP2C19 genotyping diagnostic system. All data analyses was qualitative, based on the genotype calls determined by the FRX system (using on-board automated data analysis). A printed result listing the genotype call for each SNP was generated by the FRX system at the end of each run. If the result of a test is "Inconclusive" for one or more SNPs, the test were immediately repeated for the corresponding SNP(s) only, per the instructions for use. Results are reported based on both first-pass and second-pass (i.e. repeated test). For both the first-pass and second-pass results, 1-sided 95% confidence lower limits were calculated using the score method for the % correct calls (i.e. % agreement).
Time frame: After second pass result is complete (~3h)
A total of 8 individuals were recruited for a company pool of known suspected genotypes; each with a different CYP2C19 genotype confirmed prior to the study by bi-directional sequencing.
| Milestone | *1/*1 CYP2C19 Genotype | *1/*2 CYP2C19 Genotype | *2/*2 CYP2C19 Genotype | *3/*1 CYP2C19 Genotype | *1/*17 CYP2C19 Genotype | *17/*17 CYP2C19 Genotype | *2/*3 CYP2C19 Genotype | *2/*17 CYP2C19 Genotype |
|---|---|---|---|---|---|---|---|---|
| Started | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| All genotypes confirmed with reference | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Participated in all tests | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Completed | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Reproducibility was calculated as a percentage of the correct calls over the total calls made for each genotype group. All calls were made using the Spartan FRX CYP2C19 genotyping diagnostic system. All data analyses was qualitative, based on the genotype calls determined by the FRX system (using on-board automated data analysis). A printed result listing the genotype call for each SNP was generated by the FRX system at the end of each run. If the result of a test is "Inconclusive" for one or more SNPs, the test were immediately repeated for the corresponding SNP(s) only, per the instructions for use. Results are reported based on both first-pass and second-pass (i.e. repeated test). For both the first-pass and second-pass results, 1-sided 95% confidence lower limits were calculated using the score method for the % correct calls (i.e. % agreement).
| Percentage of Correct Calls | *1/*1 CYP2C19 Genotype | *1/*2 CYP2C19 Genotype | *2/*2 CYP2C19 Genotype | *3/*1 CYP2C19 Genotype | *1/*17 CYP2C19 Genotype | *17/*17 CYP2C19 Genotype | *2/*3 CYP2C19 Genotype | *2/*17 CYP2C19 Genotype |
|---|---|---|---|---|---|---|---|---|
| Percentage of Correct Calls to Assess Reproducibility of the Spartan FRX CYP2C19 System. | 98.3 (95.1 to 99.4) | 100 (97.8 to 100) | 97.5 (95 to 98.8) | 99.2 (96.4 to 99.8) | 100 (97.8 to 100) | 99.2 (96.4 to 99.8) | 99.2 (96.4 to 99.8) | 99.2 (96.4 to 99.8) |
Collected over Adverse events were monitored for the full duration of the trial (~2 months).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| *1/*1 CYP2C19 Genotype | — | — | — |
| *1/*2 CYP2C19 Genotype | — | — | — |
| *2/*2 CYP2C19 Genotype | — | — | — |
| *3/*1 CYP2C19 Genotype | — | — | — |
| *1/*17 CYP2C19 Genotype | — | — | — |
| *17/*17 CYP2C19 Genotype | — | — | — |
| *2/*3 CYP2C19 Genotype | — | — | — |
| *2/*17 CYP2C19 Genotype | — | — | — |
| Age, Categorical(Participants) | *1/*1 CYP2C19 Genotype | *1/*2 CYP2C19 Genotype | *2/*2 CYP2C19 Genotype | *3/*1 CYP2C19 Genotype | *1/*17 CYP2C19 Genotype | *17/*17 CYP2C19 Genotype | *2/*3 CYP2C19 Genotype | *2/*17 CYP2C19 Genotype | Total |
|---|---|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Between 18 and 65 years | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 7 |
| >=65 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | *1/*1 CYP2C19 Genotype | *1/*2 CYP2C19 Genotype | *2/*2 CYP2C19 Genotype | *3/*1 CYP2C19 Genotype | *1/*17 CYP2C19 Genotype | *17/*17 CYP2C19 Genotype | *2/*3 CYP2C19 Genotype | *2/*17 CYP2C19 Genotype | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 3 |
| Male | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 1 | 5 |
| Region of Enrollment(participants) | *1/*1 CYP2C19 Genotype | *1/*2 CYP2C19 Genotype | *2/*2 CYP2C19 Genotype | *3/*1 CYP2C19 Genotype | *1/*17 CYP2C19 Genotype | *17/*17 CYP2C19 Genotype | *2/*3 CYP2C19 Genotype | *2/*17 CYP2C19 Genotype | Total |
|---|---|---|---|---|---|---|---|---|---|
| Canada | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 8 |
This study is completed, as verified in Dec 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Spartan Bioscience Inc.